226 related articles for article (PubMed ID: 25193094)
1. Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE.
Carreno JJ; Lodise TP
Infect Dis Ther; 2014 Dec; 3(2):123-32. PubMed ID: 25193094
[TBL] [Abstract][Full Text] [Related]
2. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
3. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
[TBL] [Abstract][Full Text] [Related]
4. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.
Welte T; Kantecki M; Stone GG; Hammond J
Int J Antimicrob Agents; 2019 Oct; 54(4):410-422. PubMed ID: 31404620
[TBL] [Abstract][Full Text] [Related]
5. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
[TBL] [Abstract][Full Text] [Related]
6. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Rank DR; Friedland HD; Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Frampton JE
Drugs; 2013 Jul; 73(10):1067-94. PubMed ID: 23801418
[TBL] [Abstract][Full Text] [Related]
8. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
Zhong NS; Sun T; Zhuo C; D'Souza G; Lee SH; Lan NH; Chiang CH; Wilson D; Sun F; Iaconis J; Melnick D
Lancet Infect Dis; 2015 Feb; 15(2):161-71. PubMed ID: 25539586
[TBL] [Abstract][Full Text] [Related]
9. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
File TM; Wilcox MH; Stein GE
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
[TBL] [Abstract][Full Text] [Related]
10. Ceftaroline Fosamil for the Treatment of
Vazquez JA; Maggiore CR; Cole P; Smith A; Jandourek A; Friedland HD
Infect Dis Clin Pract (Baltim Md); 2015 Jan; 23(1):39-43. PubMed ID: 25574117
[TBL] [Abstract][Full Text] [Related]
11. Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
Scott LJ
Drugs; 2016 Nov; 76(17):1659-1674. PubMed ID: 27766567
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL
Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Taboada M; Melnick D; Iaconis JP; Sun F; Zhong NS; File TM; Llorens L; Friedland HD; Wilson D
J Antimicrob Chemother; 2016 Apr; 71(4):862-70. PubMed ID: 26702925
[TBL] [Abstract][Full Text] [Related]
14. Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.
Lodise TP; Anzueto AR; Weber DJ; Shorr AF; Yang M; Smith A; Zhao Q; Huang X; File TM
Antimicrob Agents Chemother; 2015 Feb; 59(2):1119-26. PubMed ID: 25487791
[TBL] [Abstract][Full Text] [Related]
15. Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
Esposito S; Carrothers TJ; Riccobene T; Stone GG; Kantecki M
Paediatr Drugs; 2021 Nov; 23(6):549-563. PubMed ID: 34462863
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant
Torres A; Kuraieva A; Stone GG; Cillóniz C
Eur Respir Rev; 2023 Dec; 32(170):. PubMed ID: 37852658
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil.
Li J; Das S; Zhou D; Al-Huniti N
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):682-694. PubMed ID: 31044546
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
[TBL] [Abstract][Full Text] [Related]
19. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
Maggiore C; Pasquale T; Cole P; Friedland HD
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):141-53. PubMed ID: 25467425
[TBL] [Abstract][Full Text] [Related]
20. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit.
Maggiore C; Vazquez JA; Guervil DJ; Ramani A; Jandourek A; Cole P; Friedland HD
Ther Clin Risk Manag; 2015; 11():557-63. PubMed ID: 25897240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
